로딩 중…
StockDiggingStockDigging

Sam Chun Dang Pharm. Co., Ltd

000250· KOSDAQ
₩253,500-3.61%
2026-06-19

Price Chart

Sam Chun Dang Pharm. Co., Ltd+57.26%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap5.95T KRW
Revenue246.05B KRW
Net Income18.46B KRW
Total Assets573.12B KRW
Net Assets394.47B KRW
Employees417
Value
P/E322.17x
P/B15.07x
PEG0.24x
P/S24.17x
EV/EBITDA446.56x
FCF Yield-0.61%
Profitability
ROE4.68%
ROA3.22%
Op. Margin5.38%
Revenue Growth28.15%
Earnings Growth1344.03%
Financial Health
Debt Ratio145.29%
Total Debt44.71B KRW
FCF-36.35B KRW
Cash84.21B KRW
Current Ratio2.18x
Net Debt/EBITDA-2.99x
Dividend
Div. Yield0.02%
Div. Growth-75.00%
Performance
1Y Return57.26%
1M Return-26.95%
From 52W High-79.44%
1Y MDD-79.81%
Trading
Volume136,094 shares
Foreign Own.6.83%
Per Share
EPS436 KRW
BPS12,740 KRW

Company Info

CEO 전인석
Employees 417
Founded 1943
HQ 경기도 화성시, KR

Samchundang Pharm, established in 1943 and headquartered in Hwaseong-si, Gyeonggi-do, began as a pharmaceutical manufacturer and seller. By acquiring Optus Pharm in 2013, it became a leading specialized ophthalmic treatment company, producing prescription-based pharmaceuticals including antibiotics, circulatory disease treatments, digestive disease treatments, and eye drops. The company is actively expanding its global market presence by exporting finished pharmaceuticals to Vietnam, Hong Kong, and Singapore.